Signet Financial Management LLC Decreases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Signet Financial Management LLC lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 26.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 9,940 shares of the specialty pharmaceutical company’s stock after selling 3,521 shares during the quarter. Signet Financial Management LLC’s holdings in Jazz Pharmaceuticals were worth $1,223,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock worth $825,705,000 after acquiring an additional 29,960 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Jazz Pharmaceuticals by 7.5% during the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock worth $408,654,000 after acquiring an additional 184,124 shares in the last quarter. State Street Corp raised its position in shares of Jazz Pharmaceuticals by 1.8% during the 2nd quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company’s stock worth $294,106,000 after acquiring an additional 42,703 shares in the last quarter. LSV Asset Management raised its position in shares of Jazz Pharmaceuticals by 2.4% during the 3rd quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock worth $307,055,000 after acquiring an additional 55,630 shares in the last quarter. Finally, FMR LLC raised its position in shares of Jazz Pharmaceuticals by 8.1% during the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock worth $172,560,000 after acquiring an additional 100,349 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 1.8 %

NASDAQ:JAZZ opened at $108.90 on Wednesday. The firm has a market cap of $6.86 billion, a P/E ratio of 17.79, a PEG ratio of 1.53 and a beta of 0.59. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37. The stock’s 50 day simple moving average is $120.99 and its 200-day simple moving average is $122.95. Jazz Pharmaceuticals plc has a 12-month low of $108.75 and a 12-month high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Equities analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. Truist Financial reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Piper Sandler lifted their price target on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. JPMorgan Chase & Co. lifted their price target on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, March 22nd. Finally, Robert W. Baird assumed coverage on Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $195.08.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the purchase, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the purchase, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The disclosure for this sale can be found here. Company insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.